Value of PAM50 risk of recurrence score in patients with HR positive HER2 negative early breast cancer and intermediate risk: A single cancer center institution prospective observational study

被引：0
|
作者：
Nicolai, Vincent [1 ]
Gilhodes, Julia [1 ]
Lacaze, Jean Louis [1 ]
Ung, Mony [1 ]
De Maio, Eleonora [1 ]
Duprez-Paumier, Raphaelle [1 ]
Vaysse, Charlotte [1 ]
Filleron, Thomas [1 ]
Jouve, Eva [1 ]
Selmes, Gabrielles [1 ]
Franchet, Camille [1 ]
Massabeau, Carole [1 ]
Chira, Cyprian [1 ]
Izar, Francoise [1 ]
Roche, Henri [1 ]
Pradines, Anne [1 ]
Dalenc, Florence [1 ]
机构：
[1] IUCT O, Toulouse, France
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P2-18-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-18-06
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Caveolin-1 gene expression provides additional prognostic information combined with PAM50 risk of recurrence (ROR) score in breast cancer
    Christopher Godina
    Mattias Belting
    Johan Vallon-Christersson
    Karolin Isaksson
    Ana Bosch
    Helena Jernström
    Scientific Reports, 14
  • [42] PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: A meta-analysis
    Schettini, F.
    Pascual, T.
    Chic, N.
    Conte, B.
    Martinez, O.
    Adamo, B.
    Vidal, M.
    Munoz, M.
    Fernandez-Martinez, A.
    Griguolo, G.
    Guarneri, V.
    Conte, P. F.
    De Placido, S.
    Carey, L.
    Perou, C. M.
    Prat, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [43] Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER plus early breast cancer (EBC): An ABCSG study
    Gnant, M.
    Filipits, M.
    Mlineritsch, B.
    Dubsky, P.
    Jakesz, R.
    Kwasny, W.
    Fitzal, F.
    Rudas, M.
    Knauer, M.
    Singer, C.
    Greil, R.
    Ferree, S.
    Storhoff, J.
    Cowens, J. W.
    Schaper, C.
    Liu, S.
    Nielsen, T.
    CANCER RESEARCH, 2012, 72
  • [44] Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
    Morganti, Stefania
    Marra, Antonio
    Crimini, Edoardo
    D'Amico, Paolo
    Zagami, Paola
    Curigliano, Giuseppe
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 192 (03) : 465 - 484
  • [45] Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
    Stefania Morganti
    Antonio Marra
    Edoardo Crimini
    Paolo D’Amico
    Paola Zagami
    Giuseppe Curigliano
    Breast Cancer Research and Treatment, 2022, 192 : 465 - 484
  • [46] Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
    Gnant, M.
    Filipits, M.
    Greil, R.
    Stoeger, H.
    Rudas, M.
    Bago-Horvath, Z.
    Mlineritsch, B.
    Kwasny, W.
    Knauer, M.
    Singer, C.
    Jakesz, R.
    Dubsky, P.
    Fitzal, F.
    Bartsch, R.
    Steger, G.
    Balic, M.
    Ressler, S.
    Cowens, J. W.
    Storhoff, J.
    Ferree, S.
    Schaper, C.
    Liu, S.
    Fesl, C.
    Nielsen, T. O.
    ANNALS OF ONCOLOGY, 2014, 25 (02) : 339 - 345
  • [47] First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer
    Dieci, Maria Vittoria
    Guarneri, Valentina
    Giarratano, Tommaso
    Mion, Marta
    Tortora, Giampaolo
    De Rossi, Costanza
    Gori, Stefania
    Oliani, Cristina
    Merlini, Laura
    Pasini, Felice
    Bonciarelli, Giorgio
    Griguolo, Gaia
    Orvieto, Enrico
    Michieletto, Silvia
    Saibene, Tania
    Del Bianco, Paola
    De Salvo, Gian Luca
    Conte, PierFranco
    ONCOLOGIST, 2018, 23 (03): : 297 - 305
  • [48] Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.
    Olson, E. M.
    Flores, L. M.
    Najita, J. S.
    Curley, C.
    Jeong, J.
    Murray, K.
    Savoie, J. J.
    Winer, E. P.
    Krop, I. E.
    CANCER RESEARCH, 2011, 71
  • [49] Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer
    Teran, Santiago
    Alva, Manuel
    Tolosa, Pablo
    Rey-Cardenas, Macarena
    Madariaga, Ainhoa
    Lema, Laura
    Ruano, Yolanda
    Manso, Luis
    Ciruelos, Eva
    Sanchez-Bayona, Rodrigo
    BREAST, 2023, 71 : 42 - 46
  • [50] Clinical-risk assessment of ER positive, Her2 negative breast cancer patients: Correlation between the average modified magee score and mammaprint
    Katerji, Hani
    Zhang, Huina
    Hicks, David
    Turner, Bradley M.
    CANCER RESEARCH, 2022, 82 (04)
12345